» Articles » PMID: 36405987

Updates on the Diagnosis and Management of Glaucoma

Overview
Specialty Health Services
Date 2022 Nov 21
PMID 36405987
Authors
Affiliations
Soon will be listed here.
Abstract

Glaucoma is the leading cause of blindness throughout the world (after cataracts); therefore, general physicians should be familiar with the diagnosis and management of affected patients. Glaucomas are usually categorized by the anatomy of the anterior chamber angle (open vs narrow/closed), rapidity of onset (acute vs chronic), and major etiology (primary vs secondary). Most glaucomas are primary (ie, without a contributing comorbidity); however, several coexisting ophthalmic conditions may serve as the underlying etiologies of secondary glaucomas. Chronic glaucoma occurs most commonly; thus, regular eye examinations should be performed in at-risk patients to prevent the insidious loss of vision that can develop before diagnosis. Glaucoma damages the optic nerve and retinal nerve fiber layer, leading to peripheral and central visual field defects. Elevated intraocular pressure (IOP), a crucial determinant of disease progression, remains the only modifiable risk factor; thus, all current treatments (medications, lasers, and operations) aim to reduce the IOP. Pharmacotherapy is the usual first-line therapy, but noncompliance, undesirable adverse effects, and cost limit effectiveness. Laser and surgical treatments may lower IOP significantly over long periods and may be more cost effective than pharmacotherapy, but they are plagued by greater procedural risks and frequent treatment failures. Traditional incisional procedures have recently been replaced by several novel, minimally invasive glaucoma surgeries with improved safety profiles and only minimal decreases in efficacy. Minimally invasive glaucoma surgeries have dramatically transformed the surgical management of glaucoma; nevertheless, large, randomized trials are required to assess their long-term efficacy.

Citing Articles

Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review.

Kharisova C, Kitaeva K, Solovyeva V, Sufianov A, Sufianova G, Akhmetshin R Biomedicines. 2025; 13(2).

PMID: 40002778 PMC: 11852528. DOI: 10.3390/biomedicines13020365.


Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation.

Vagiakis I, Papadopoulou E, Amaxilati E, Tsiropoulos G, Konstas A, Panos G Drug Des Devel Ther. 2025; 19:703-714.

PMID: 39906697 PMC: 11792881. DOI: 10.2147/DDDT.S506520.


Advancements and Prospects in Nanorobotic Applications for Ophthalmic Therapy.

Menezes Ferreira A, da Silva Felix J, Chaves de Lima R, Martins de Souza M, Sousa Dos Santos J ACS Biomater Sci Eng. 2025; 11(2):958-980.

PMID: 39818739 PMC: 11815637. DOI: 10.1021/acsbiomaterials.4c02368.


A case of uveoscleral mucosa-associated lymphoid tissue lymphoma with secondary angle-closure glaucoma.

Mitamura M, Kase S, Suimon Y, Kato K, Kanno-Okada H, Ishida S BMC Ophthalmol. 2024; 24(1):549.

PMID: 39731017 PMC: 11674132. DOI: 10.1186/s12886-024-03825-8.


Fecal microbiota transplantation for glaucoma; a potential emerging treatment strategy.

Ebrahimi R, Farsi Y, Nejadghaderi S Curr Res Microb Sci. 2024; 7:100314.

PMID: 39726974 PMC: 11670420. DOI: 10.1016/j.crmicr.2024.100314.


References
1.
Serle J, Katz L, McLaurin E, Heah T, Ramirez-Davis N, Usner D . Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2017; 186:116-127. DOI: 10.1016/j.ajo.2017.11.019. View

2.
Weinreb R, Scassellati Sforzolini B, Vittitow J, Liebmann J . Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology. 2016; 123(5):965-73. DOI: 10.1016/j.ophtha.2016.01.019. View

3.
Kwon Y, Fingert J, Kuehn M, Alward W . Primary open-angle glaucoma. N Engl J Med. 2009; 360(11):1113-24. PMC: 3700399. DOI: 10.1056/NEJMra0804630. View

4.
Ritch R, Tham C, Lam D . Argon laser peripheral iridoplasty (ALPI): an update. Surv Ophthalmol. 2007; 52(3):279-88. DOI: 10.1016/j.survophthal.2007.02.006. View

5.
Guedes R, Gravina D, Lake J, Guedes V, Chaoubah A . One-Year Comparative Evaluation of iStent or iStent inject Implantation Combined with Cataract Surgery in a Single Center. Adv Ther. 2019; 36(10):2797-2810. PMC: 6822971. DOI: 10.1007/s12325-019-01067-5. View